Zealand Pharma CMO: Rival's delay is beneficial for Zealand

FDA has extended the review time for glucagon rescue pens from Danish Zealand Pharma's US rivals. Zealand's Chief Medical and Development Officer, Adam Steensberg, calls it beneficial for the company and is not scared of encountering the same problems.

Photo: Zealand Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles